Abstract：
Distinguishing cutaneous malignant melanoma (CMM) from nevi can be clinically challenging. Suspicious lesions are therefore excised, resulting in many benign lesions being removed surgically to find 1 CMM. It has been proposed to use tape strip derived ribonucleic acid (RNA) to distinguish CMM from nevi.
To develop this technique further and validate if RNA profiles can rule out CMM in clinically suspicious lesions with 100% sensitivity.
Before surgical excision, 200 lesions clinically assessed as CMM were tape stripped. Expression levels of 11 genes on the tapes were investigated by RNA measurement and used in a rule-out test.
Histopathology showed that 73 CMMs and 127 non-CMMs were included. Our test correctly identified all CMMs (100% sensitivity) based on the expression levels of 2 oncogenes, PRAME and KIT, relative to a housekeeping gene. Patient age and sample storage time were also significant. Simultaneously, our test correctly excluded CMM in 32% of non-CMM lesions (32% specificity).
Our sample contained a very high proportion of CMMs, perhaps due to inclusion during COVID-19 shutdown. Validation in a separate trial must be performed.
Our results demonstrate that the technique can reduce removal of benign lesions by one-third without overlooking any CMMs.
To develop this technique further and validate if RNA profiles can rule out CMM in clinically suspicious lesions with 100% sensitivity.
Before surgical excision, 200 lesions clinically assessed as CMM were tape stripped. Expression levels of 11 genes on the tapes were investigated by RNA measurement and used in a rule-out test.
Histopathology showed that 73 CMMs and 127 non-CMMs were included. Our test correctly identified all CMMs (100% sensitivity) based on the expression levels of 2 oncogenes, PRAME and KIT, relative to a housekeeping gene. Patient age and sample storage time were also significant. Simultaneously, our test correctly excluded CMM in 32% of non-CMM lesions (32% specificity).
Our sample contained a very high proportion of CMMs, perhaps due to inclusion during COVID-19 shutdown. Validation in a separate trial must be performed.
Our results demonstrate that the technique can reduce removal of benign lesions by one-third without overlooking any CMMs.
摘要：
背景：区分皮肤恶性黑色素瘤（CMM）和痣可能在临床上具有挑战性。因此，可疑病变被切除，导致许多良性病变被手术切除以找到1个CMM。已经提出使用胶带条衍生的核糖核酸(RNA)来区分CMM与痣。
目的：进一步开发此技术，并验证RNA谱是否可以以100％的敏感性排除临床可疑病变中的CMM。
方法：手术切除前，将200个临床评估为CMM的病变剥离胶带。通过RNA测量研究胶带上11个基因的表达水平，并用于排除测试。
结果：组织病理学显示包括73个CMM和127个非CMM。我们的测试根据2个癌基因的表达水平正确识别了所有CMM（100％灵敏度），PRAME和KIT,相对于管家基因。患者年龄和样品储存时间也是显著的。同时,我们的测试正确排除了32%的非CMM病变中的CMM(32%特异性).
结论：我们的样本包含非常高比例的CMM，可能是由于在COVID-19关闭期间纳入。必须在单独的试验中进行验证。
结论：我们的结果表明，该技术可以在不忽略任何CMM的情况下将良性病变的切除减少三分之一。
目的：进一步开发此技术，并验证RNA谱是否可以以100％的敏感性排除临床可疑病变中的CMM。
方法：手术切除前，将200个临床评估为CMM的病变剥离胶带。通过RNA测量研究胶带上11个基因的表达水平，并用于排除测试。
结果：组织病理学显示包括73个CMM和127个非CMM。我们的测试根据2个癌基因的表达水平正确识别了所有CMM（100％灵敏度），PRAME和KIT,相对于管家基因。患者年龄和样品储存时间也是显著的。同时,我们的测试正确排除了32%的非CMM病变中的CMM(32%特异性).
结论：我们的样本包含非常高比例的CMM，可能是由于在COVID-19关闭期间纳入。必须在单独的试验中进行验证。
结论：我们的结果表明，该技术可以在不忽略任何CMM的情况下将良性病变的切除减少三分之一。
